创新药沪深港ETF（517110）涨超1.6%，医药板块的情绪和估值抬升的空间或进一步打开

Group 1 - The core viewpoint is that China's innovative drug BD (business development) transactions are experiencing significant growth in both volume and quality since 2024, with notable increases in upfront payments and total package amounts, indicating international recognition of Chinese innovative drugs [1] - At the 2025 AACR conference, 126 companies showcased nearly 300 research results, with the number of Chinese companies and displayed results reaching historical highs, reflecting international academic recognition of domestic innovative drugs [1] - Despite ongoing US-China tariff frictions since April, multiple BD transactions for drugs have still been completed, demonstrating the strong momentum of innovative drugs going abroad [1] Group 2 - The innovative drug ETF (517110) tracks the SHS Innovative Drug (RMB) Index (931409), which is compiled by China Securities Index Co., Ltd., selecting listed companies involved in the research, production, and sales of innovative drugs from the A-share market [2] - The index aims to reflect the overall performance of innovative drug-related companies in the A-share market, with constituent stocks characterized by significant R&D investment and growth potential [2] - The innovative drug sector is expected to benefit from outbound transactions, AI empowerment across the pharmaceutical industry, and the implementation of innovative drug category B medical insurance, leading to potential increases in profitability and valuation [1]